NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity PA-19-271 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA), issued by the National Institutes of Health (NIH), invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) grant applications. United States SBCs that have the research capabilities and technological expertise to contribute to the R and D mission(s) of the NIH awarding components identified in this FOA are encouraged to submit STTR grant applications in response to identified topics (see PHS 2019-2 SBIR/STTR Program Descriptions and Research Topics for NIH. This Parent Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.
Funding Opportunity PA-19-270 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA), issued by the National Institutes of Health (NIH), invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) grant applications. United States SBCs that have the research capabilities and technological expertise to contribute to the R and D mission(s) of the NIH awarding components identified in this FOA are encouraged to submit STTR grant applications in response to identified topics (see PHS 2019-2 SBIR/STTR Program Descriptions and Research Topics for NIH. This Parent Funding Opportunity Announcement does not accept clinical trials.
Funding Opportunity PA-19-273 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA), issued by the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA), invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) grant applications. United States SBCs that have the research capabilities and technological expertise to contribute to the R and D mission(s) of the NIH, CDC, and FDA awarding components identified in this FOA are encouraged to submit SBIR grant applications in response to identified topics (see PHS 2019-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA. This Parent Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.
Funding Opportunity PA-19-272 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA), issued by the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA), invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) grant applications. United States SBCs that have the research capabilities and technological expertise to contribute to the R and D mission(s) of the NIH, CDC, and FDA awarding components identified in this FOA are encouraged to submit SBIR grant applications in response to identified topics (see PHS 2019-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA. This Parent Funding Opportunity Announcement does not accept clinical trials.
Notice NOT-NS-19-063 from the NIH Guide for Grants and Contracts
Notice NOT-ES-19-013 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-19-269 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications that propose Artificial Intelligence (AI), Machine Learning (ML), and/or Deep Learning (DL) approaches, collectively referred to here as "cognitive systems," that lead to the identification of gene mutations/variants that cause or contribute to the risk of or protection against the development of Alzheimers disease (AD) and Alzheimer's disease related dementias (ADRD) via analysis of a variety of genetic, genomic, and biomarker data that are currently available to the research community.
Notice NOT-CA-19-049 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AG-20-017 from the NIH Guide for Grants and Contracts. This FOA is intended to advance scientific understanding of lucidity in dementia by supporting an initial set of retrospective and/or prospective studies that will lay the groundwork for further research on this topic. Studies supported by this FOA will use the R21/R33 phased innovation mechanism to support initial exploratory/developmental aims during the R21 phase followed by further expanded aims during the R33 phase.
Funding Opportunity RFA-AG-20-016 from the NIH Guide for Grants and Contracts. This FOA is intended to advance scientific understanding of lucidity in dementia by supporting an initial set of retrospective and/or prospective studies that will lay the groundwork for further research on this topic. Studies supported by this FOA will use the R21 mechanism to support initial exploratory/developmental aims that will serve as the foundation for future studies.
Notice NOT-DA-19-033 from the NIH Guide for Grants and Contracts
Notice NOT-TW-19-004 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-19-267 from the NIH Guide for Grants and Contracts. Funding Opportunity PurposeThe purpose of this NIH Mentored Research Scientist Development Award (K01) is to provide salary and research support to investigators who are within ten years of completing their terminal professional degree or residency training. Research and mentorship must be in the field of HIV/AIDS translational studies, using nonhuman primates (NHPs) as pre-clinical models. These awards will provide 3 years of support for intensive research career development under the guidance of an experienced mentorship team, with expertise in both the pre-clinical application of NHP HIV/AIDS models and in translation of the results from such studies to clinical application in humans. The expectation is that through this sustained period of research career development and training, awardees will launch independent research careers and become competitive for new research project grant (e.g., R01) funding. This funding initiative addresses all objectives of the fiscal year (FY) 2019/2020 NIH strategic plan for HIV and HIV-Related Research (https://www.oar.nih.gov/hiv-policy-and-research/strategic-plan), including research directed towards prevention and cure of HIV infection; next-generation therapies; understanding the roles of comorbidities, coinfections and complications; and cross-cutting activities such as research training and building capacity.
Funding Opportunity PAR-19-268 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages Research Conference Grant (R13) applications to conduct an annual intensive workshop/conference/meeting that addresses the needs of early stage HIV/AIDS researchers utilizing nonhuman primates (NHPs) as they translate preclinical research from NHPs to human clinical trials. The objectives of the meeting(s) supported by this FOA are to provide these early stage HIV/AIDS researchers with guidance on conducting preclinical research to inform clinical trials on reducing the incidence of HIV/AIDS infection, including vaccine development and testing; developing next-generation HIV therapies, including potential cure therapies; treatment of HIV-associated coinfections, comorbidities and complications; and infection prevention strategies. In addition to guidance on translating results to clinical trials, the conference should target developing skills related to networking, grantsmanship, and goal/milestone-driven projects. Conference topics should also include other considerations such as statistical and host genetics considerations; methods to translate the results of NHP studies to clinical trials in humans; and how to develop new NHP research programs to better reflect clinical observations and findings in human HIV/AIDS patients.
Funding Opportunity RFA-AI-19-041 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications from investigators to participate in the HLA and KIR Region Genomics in Immune Mediated Diseases Consortium (HLARGC). This cooperative research group supports projects defining the association between variations in the human leukocyte antigen (HLA), also known as the Major Histocompatibility Complex (MHC), and natural killer cell immunoglobulin-like receptor (KIR) genetic regions and immune-mediated diseases, including outcomes following cell, tissue, and organ transplantation.
Funding Opportunity RFA-AI-19-044 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications from investigators to participate in the HLA and KIR Region Genomics in Immune Mediated Diseases Consortium (HLARGC). This cooperative research group supports projects defining the association between variations in the human leukocyte antigen (HLA), also known as the Major Histocompatibility Complex (MHC), and natural killer cell immunoglobulin-like receptor (KIR) genetic regions and immune-mediated diseases, including outcomes following cell, tissue, and organ transplantation.
Notice NOT-HD-19-010 from the NIH Guide for Grants and Contracts
Notice NOT-OD-19-104 from the NIH Guide for Grants and Contracts
Notice NOT-OD-19-100 from the NIH Guide for Grants and Contracts
Notice NOT-HL-19-698 from the NIH Guide for Grants and Contracts